Martin-Vicente: Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients [HCQ]

Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients

Martin-Vicente et al., medRxiv, doi:10.1101/2021.03.08.21253121 (Preprint)

Martin-Vicente et al., Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in.., medRxiv, doi:10.1101/2021.03.08.21253121 (Preprint)

Mar 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 92 ICU patients with almost all treated with HCQ and only one non-HCQ treated patient that died, showing unadjusted non-statistically significant lower mortality with treatment. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; treatment or control group size extremely small.

Important missing comments or errors? Let us know.

risk of death, 59.3% lower, RR 0.41, p = 0.41, treatment 37 of 91 (40.7%), control 1 of 1 (100.0%), NNT 1.7.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Martin-Vicente et al., 8 Mar 2021, retrospective, Spain, preprint, 38 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21253121; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients María Martin-Vicente 1*, Raquel Almansa 2,3,4*, Isidoro Martínez 1*, Ana P. Tedim2,3, Elena Bustamante 2,5, Luis Tamayo2,6, César Aldecoa 2,7,8, José Manuel Gómez9, Gloria Renedo5, Jose Ángel Berezo6, Jamil Antonio Cedeño9, Nuria Mamolar5, Pablo García Olivares9, Rubén Herrán2,6, Ramón Cicuendez5, Pedro Enríquez2,6, Alicia Ortega2,3, Noelia Jorge2,3,4, Amanda de la Fuente2,3, Juan Bustamante-Munguira10, María José Muñoz-Gómez1, Milagros González-Rivera11, Carolina Puertas11, Vicente Más 12, Mónica Vázquez12 , Felipe PérezGarcía13, Jesús Rico-Feijoo 2,8, Silvia Martín2,8, Anna Motos4,14, Laia Fernandez-Barat 4,14, Jose María Eiros15, Marta Dominguez-Gil15, Ricard Ferrer4,16, Ferrán Barbé 4,17, David J Kelvin4,18,19†, Jesús F Bermejo-Martin 2,3,4†, Salvador Resino 1†, Antoni Torres4,14†. *These authors contributed equally † These authors contributed equally 1. Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. 2. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain 3. Hospital Universitario Río Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 4. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21253121; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 5. Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud. Av. Ramón y Cajal, 3, 47003 Valladolid, Spain 6. Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 7. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain. 8. Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 9. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain. 10. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid. Gerencia Regional de Salud, Av. Ramón y Cajal, 3, 47003 Valladolid, Spain 11. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain. 12. Unidad de Biología Viral, Centro Nacional de Microbiología,..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit